Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026)
Lemaitre Vascular (LMAT) posted quarterly Total Non-Current Liabilities of $221.6 million for Q1 2026, up 6.76% year-over-year from $207.6 million in Q1 2025, and little changed quarter-over-quarter from $220.7 million in Q4 2025.
Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Lemaitre Vascular (LMAT) has reported Total Non-Current Liabilities for 17 consecutive years, with $221.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 6.76% year-over-year to $221.6 million; the TTM figure through Mar 2026 stood at $221.6 million (up 6.76% YoY), while the FY2025 annual figure was $220.7 million, up 3.28% from the prior year.
- Total Non-Current Liabilities was little changed at $221.6 million in Q1 2026 per LMAT's latest filing, from $220.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $221.6 million in Q1 2026 and bottomed at $33.9 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $103.1 million across 5 years, with a median of $44.9 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 51.37% — and 2025, when it surged 417.24%.
- Lemaitre Vascular's Total Non-Current Liabilities stood at $40.1 million in 2022, then gained by 16.21% to $46.6 million in 2023, then surged by 358.48% to $213.7 million in 2024, then climbed by 3.28% to $220.7 million in 2025, then advanced by 0.4% to $221.6 million in 2026.
- Business Quant data shows LMAT's Total Non-Current Liabilities at $221.6 million in Q1 2026, $220.7 million in Q4 2025, and $218.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 135.11 Bn | 129.89 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.51 Bn | 51.65 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.73 Bn | 34.38 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.94 Bn | 32.47 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.02 Bn | 26.34 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 24.95 Bn | 24.51 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.28 Bn | 14.87 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.83 Bn | 14.69 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.65 Bn | 11.50 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Lemaitre Vascular | 1.88 Bn | 1.51 Bn | 50.76 Mn | 218.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.75 Mn |
| Mar 31, 2026 | 221.59 Mn |
| Dec 31, 2025 | 220.71 Mn |
| Sep 30, 2025 | 218.21 Mn |
| Jun 30, 2025 | 213.97 Mn |
| Mar 31, 2025 | 207.56 Mn |
| Dec 31, 2024 | 213.70 Mn |
| Sep 30, 2024 | 45.69 Mn |
| Jun 30, 2024 | 41.37 Mn |
| Mar 31, 2024 | 44.86 Mn |
| Dec 31, 2023 | 46.61 Mn |
| Sep 30, 2023 | 43.23 Mn |
| Jun 30, 2023 | 42.06 Mn |
| Mar 31, 2023 | 40.51 Mn |
| Dec 31, 2022 | 40.11 Mn |
| Sep 30, 2022 | 38.40 Mn |
| Jun 30, 2022 | 40.70 Mn |
| Mar 31, 2022 | 33.90 Mn |
| Dec 31, 2021 | 38.51 Mn |
| Sep 30, 2021 | 40.29 Mn |